FIELD: biotechnology.
SUBSTANCE: bispecific antibody is proposed, which specifically binds to CD47 and PD-L1. The invention also relates to nucleic acid encoding this antibody, an expression vector, a method for the production of an antibody, and to the use of antibodies and compositions including the specified antibodies in cancer therapy.
EFFECT: invention provides for specific high-affine binding of CD47 and PD-L1 and reduction in undesired effects.
23 cl, 17 dwg, 11 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION PROTEIN AND ITS USE | 2020 |
|
RU2811120C2 |
| ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
